MAHFOUZ EL SHAHAWY, MD, MS, FACP, FCCP, FESC, FSCCT, FASH, FASPC. FAHA, FACC
Dr. Mahfouz El Shahawy, MD has devoted much of his time over the past 40 years in
advancing procedures that can help doctors identify patients with early sub-clinical
evidence of CVD, and place them on therapeutic path to prevent a heart attack and or stroke.
Dr. Shahawy works on at least 10 active medical research trials at any given time, and is
a frequent lecturer on topics of cardiology at symposia, congresses and annual conferences
on every continent. He has authored or co-authored over 200 abstracts and research
papers, and published original work which was performed at the Mayo Clinic in Rochester,
Minnesota on the Effect of Magnesium Deficiency and Thyroid Hormone on the Heart.
Dr. Shahawy has also been leading author of recent original article published in
September 15, 2017 in the American Journal of cardiology entitled efficacy and safety of
Alirocumab versus ezetimibe over 2 years [ from Odyssey combo II] and co Author on
related topic on March 15, 2015 in the New England Journal of Medicine entitled: Efficacy
and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events.
In the past few years, Dr. Shahawy has been honored with multiple awards recognizing
his professional skills and accomplishments, of particular note is his receipt of the Golden
Doctor Diploma from the University of Vienna Austria in June 2014. He has been included in
respected lists of top doctors in America and being named to the US News list of Top
Doctors from 2011-2014.along with recent recognition by the European Society of
cardiology/ EuroPrevent 2017 where he was awarded the best of original scientific work in
category of diabetes/lipids/obesity during the annual meeting in Malaga Spain April 2017.
Dr. Shahawy graduated first in his class as Sum Cum Laude from the University of
Vienna Austria, under the auspices of the President of Austria who personally bestowed
the Golden Ring of Honor on Dr. Shahawy in a special ceremony (June 1962). Dr. Shahawy
was the first non Austrian in the history of Vienna Medical School to achieve that honor.
Dr Shahawy subsequently underwent postgraduate training in Internal Medicine and
Cardiology at the world renowned University Hospital in Vienna [Algmeines Krankehouse]
Dr Shahawy moved 50 years ago [June 1967 ]to the U.S. He spent one year at the
New York Medical Center, thereafter moved to the Mayo Clinic in Rochester, Minnesota for
post graduate training in Internal Medicine and Cardiology until 1971. During his time at the
Mayo Clinic he also obtained his Master's degree from the University of Minnesota on the
Effect of Magnesium Deficiency on the Heart. After completion of 3 years as a fellow at the
Mayo Clinic, Dr Shahawy served as senior fellow and junior faculty member in the Division of
Cardiology at the Medical College of Georgia.
In July 1973, Dr. Shahawy joined the faculty at the University of Florida in the Division of
Cardiology. Dr Shahawy maintains his association with the University of Florida, where
he is currently Clinical Professor in Medicine/Cardiology. Dr Shahawy also serves as Clinical
Professor at the University of South Florida. He was also the founder and first Medical
Director for the Cardiovascular Disease Prevention Program at:
Sarasota Memorial Hospital in
Sarasota, Florida (one of the top 50 hospitals in the US).
Dr. Shahawy has been serving as the President of the Cardiovascular Center of
Sarasota since 1975 and serves as the Founder and Medical Director for the Cardiovascular
Health Assessment Center of Sarasota since 2008.
Dr. Shahawy is certified by the American Board of Internal Medicine, American Board of
Cardiovascular Disease and the Certification Board of Cardiovascular Computed
Tomography. He is also a member and fellow of numerous national and international
organizations, including the American Colleges of Physicians, Cardiology, Chest Physicians,
AHA European Society of Cardiology and an alumni of Vienna Medical School, Mayo Clinic
and Mayo Doctor's Society. and currently serves as the President of the International Society
for Cardiovascular Disease Prevention [ISCVP]